Finerenone, marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart …

Mar 25, 2025 · Finerenone is a new mineralocorticoid receptor antagonist that does not have a steroid skeleton, and in two large-scale clinical studies targeting patients with chronic kidney …

Aug 23, 2023 · Kerendia (finerenone) is a FDA approved tablet taken once a day by adults who have chronic kidney disease from type 2 diabetes. Kerendia is used to slow down kidney …

Jul 23, 2024 · What is finerenone? Finerenone is used in adults with chronic kidney disease related to diabetes mellitus type 2, to reduce the risk of: kidney problems getting worse; a …

Sep 13, 2024 · Learn about the side effects of finerenone, from common to rare, for consumers and healthcare professionals.

Oct 23, 2020 · Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) …

Mar 1, 2025 · Finerenone is used to lower the risk of serious kidney and heart problems (eg, kidney function decline, end-stage kidney disease, cardiovascular death, heart attack, and …

Finerenone is used to treat adults with chronic kidney disease (damage to the kidneys which may worsen over time and may cause the kidneys to stop working) due to type 2 diabetes.

Sep 1, 2024 · Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection …

FDA has approved Kerendia (finerenone) tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal hearts attacks, and hospitalization for heart …